Factor V (Coagulation Factor V)

Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.

Also Known As:

Networked: 1917 relevant articles (27 outcomes, 153 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Yang, Vincent W: 15 articles (01/2022 - 05/2007)
2.	Castoldi, Elisabetta: 13 articles (07/2020 - 09/2002)
3.	Akar, Nejat: 13 articles (11/2013 - 03/2003)
4.	Castoldi, E: 12 articles (01/2019 - 03/2000)
5.	Akar, N: 12 articles (01/2008 - 02/2000)
6.	Peyvandi, Flora: 11 articles (11/2019 - 10/2002)
7.	Dahlbäck, Björn: 11 articles (05/2016 - 10/2002)
8.	Bialkowska, Agnieszka B: 10 articles (01/2022 - 01/2008)
9.	Chen, Ceshi: 10 articles (10/2021 - 07/2011)
10.	Liu, Rong: 10 articles (10/2021 - 07/2011)

Related Diseases

1.	Activated Protein C Resistance (APC Resistance) 11/01/1997 - "Coatest APC Resistance V and Accélérimat were proven to be the methods most able to discriminate for factor V:Q506, while normalization was not shown to improve the screening performance. " 05/01/1998 - "Predilution of patient plasma with factor V-deficient plasma results in improved sensitivity and specificity of the COATEST APC Resistance Kit, thus offering a simple modification to enhance APC resistance determination in the routine clinical laboratory setting." 11/01/1996 - "Improved characteristics of aPC-resistance assay: Coatest aPC resistance by predilution of samples with factor V deficient plasma." 08/15/1997 - "Moreover, the study of 10 patients with APC resistance in the absence of the factor V R506Q mutation showed a 50-fold higher frequency of HR2 homozygotes. " 09/01/1996 - "Subsequent studies identified a point mutation in the gene for factor V as the underlying cause of APC-Resistance. "
2.	Hemorrhage 02/01/1993 - "Bleeding was unrelated to absolute fall in factor V level, but cessation of hemorrhage appeared to correlate with improvement in factor V level. " 08/28/2019 - "Further large studies are still called for, to correlate the grade of hemorrhage and the factor V level at birth." 07/01/2016 - "The study was designed to investigate the 5 year old girl with rare bleeding disorder -deficiency of coagulation factor V. The diagnosis was based on detail family history, physical examination and para-clinical data analyses. " 10/21/2023 - "Coagulation factor V (FV) deficiency is a rare bleeding disorder that is usually managed with fresh-frozen plasma. " 01/01/2023 - "Congenital coagulation factor V deficiency (FVD) is a rare, autosomal recessive bleeding disorder. "
3.	Hemophilia A (Haemophilia) 04/01/2014 - "Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A--an Israeli-German multicenter database study." 10/01/1977 - "Immunological studies in combined factor V and factor VIII deficiency." 07/01/2022 - "A Combined Factor V and Factor VIII Deficiency: A Case Report." 01/01/2022 - "A distinct common p.Gln317* mutation among causative LMAN1 genetic mutations of combined factor V and factor VIII deficiency in five Taiwanese families." 09/01/2019 - "Attenuation of phenotypical expression of severe hemophilia A in presence of simultaneous prothrombotic Factor V mutation: The debate continues."
4.	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 12/01/2019 - "We found that the expression level of miR-141-3p was significantly downregulated, while that of tumor necrosis factor receptor-associated factor 5 (TRAF5) was strongly upregulated in tissues from patients with T-ALL compared with healthy controls. " 02/01/2010 - "The major findings derived from these ALL-BFM trials were as follows: (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX; (2) omission of delayed re-intensification severely impaired outcome of low-risk patients; (3) 6-month-less maintenance therapy caused an increase in systemic relapses; (4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; (5) condensed induction therapy resulted in significant improvement of outcome; (6) the daunorubicin dose in induction could be safely reduced in low-risk patients and (7) intensification of consolidation/re-intensification treatment led to considerable improvement of outcome in HR patients." 05/01/2013 - "The major findings derived from these ALL-BFM trials were as follows: 1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk ALL patients and eliminated in non-high-risk non-T-ALL patients, if it was replaced by high-dose and intrathecal methotrexate; 2) omission of delayed reintensification severely impaired outcome of low-risk patients; 3) 6 months less maintenance therapy caused an increase in systemic relapses; 4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; 5) condensed induction therapy resulted in a significant improvement of outcome; 6) the daunorubicin dose in induction could be safely reduced in low-risk patients; 7) intensification of consolidation/reintensification treatment led to considerable improvement of outcome in high-risk patients."
5.	Thrombosis (Thrombus) 12/01/2015 - "Our study does not support the notion that factor V HR2 haplotype might be a risk factor for thrombosis despite its high prevalence among patients with PE." 02/01/2009 - "At multivariate study, RP percentage, factor V levels, and aAPCR were independently associated with an increased risk of thrombosis. " 01/01/2003 - "The dual role of factor V as a coagulatory and anticoagulatory cofactor permits the assumption that further mutations in the factor V gene are of importance in the study of the risk of thrombosis. " 09/01/1997 - "Due to the high prevalence of C677T MTHFR, it is likely that previous studies, which did not look for this mutation, overestimated the relative risk of thrombosis associated with factor V:Q506 alone." 04/01/1995 - "In this study, patients with FV Q506 were of a younger age and had a higher incidence of extensive thrombosis or recurrence as compared to those with the normal factor V gene. "

Related Drugs and Biologics

1.	Prothrombin (Factor II)
2.	factor V Leiden
3.	Fibrinogen (Factor I)
4.	Factor V (Coagulation Factor V)
5.	Factor VIII (Coagulation Factor VIII)
6.	Proteins (Proteins, Gene)
7.	Blood Coagulation Factors (Coagulation Factor)
8.	Antibodies
9.	Prednisone (Sone)
10.	Daunorubicin (Cerubidine)

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy
3.	Estrogen Replacement Therapy
4.	Catheters
5.	Hormone Replacement Therapy (Therapy, Hormone Replacement)